ANIP Q1 2023 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$107M+65.6% YoY

Gross Profit

$69M64.7% margin

Operating Income

$10M9.3% margin

Net Income

$1M1.3% margin

EPS (Diluted)

$0.06

QoQ Revenue Growth

+13.3%

Cash Flow

Operating Cash Flow

$21M

Free Cash Flow

$19M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$765M

Total Liabilities

$426M

Stockholders' Equity

$339M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$107M	$64M	+65.6%
Gross Profit	$69M	$30M	+128.7%
Operating Income	$10M	-$19M	+151.5%
Net Income	$1M	-$20M	+107.1%

Revenue Segments

Generics, Established Brands, and Other

$90M85%

Rare Disease

$16M15%

Geographic Segments

United States

$106M99%

Canada

$565,0001%